Pay in 4 interest-free payments of $6.92 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Your states rules in this area will set practical limits on how you develop your treatment policies and procedures
PT-141 Research# PT-141 completed the full drug development pathway: RECONNECT trials : Two Phase 3 pivotal trials in premenopausal women with HSDD demonstrated statistically significant improvements in sexual desire scores compared to placebo, with a meaningful increase in satisfying sexual events FDA approval : Approved June 21, 2019, as Vyleesi for HSDD in premenopausal women Male sexual dysfunction : Earlier trials explored PT-141 for male erectile dysfunction, though this indication was not pursued to approval Dose limitations : FDA label restricts use to no more than 8 doses per month and recommends against use in patients with uncontrolled hypertension or cardiovascular disease Post-marketing : Ongoing pharmacovigilance with established adverse event reporting The regulatory gap between MT-2 and PT-141 is the fundamental differentiator: PT-141 has undergone the rigorous efficacy and safety evaluation required for FDA approval, while MT-2 has not
Regulatory note: gonadorelin's own branded products (Factrel and Lutrepulse) were FDA-approved in the past but have since been discontinued commercially, and no FDA-approved gonadorelin product is currently marketed in the U.S
PMID: 41737537 Chem Pharm Bull The Application of Microsampling Disks in Circular Dichroism Spectroscopy for Peptide and Nucleic Acid Drugs
Less Common New mole formation Headaches These typically resolve with continued use or dose adjustment
Injectables like Ozempic or Wegovy begin at a lower weekly dose of 0.25 mg, gradually increasing to 1 mg (Ozempic) or up to 2.4 mg (Wegovy)
